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1. Main Messages
•	 Maintenance	renal	dialysis	therapy	is	very	expensive	and	an	inefficient	use	of	health	resources	based	on	cost-
effectiveness.
•	 However,	the	widespread	adoption	of	renal	dialysis	indicates	that	the	‘rule	of	rescue’	has	been	adopted	–	‘an	
ethical	imperative	to	save	individual	lives	even	when	money	might	be	more	efficiently	spent	to	prevent	deaths	
in	the	larger	population’	Doughety,	1993.	On	the	other	hand,	screening	for	Chronic	Kidney	Disease	followed	by	
treatment	with	ACE-inhibitor	drugs	is	very	cost-effective	in	people	with	diabetes	of	all	ages.
•	 Screening	for	Chronic	Kidney	Disease	followed	by	treatment	with	ACE-inhibitor	drugs	is	also	cost-effective	in	
people	who	do	not	have	diabetes	from	age	50	onwards.
•	 Given	the	very	high	cost	of	renal	replacement	therapy	in	people	with	end-stage	kidney	failure,	it	is	strongly	
recommended	that	screening	for	Chronic	Kidney	Disease	be	implemented	for	all	Australians	over	the	age	of	50	
and	all	diabetics	regardless	of	age.
2. Background
Kidney	disease	has	significant	impacts	on	quality	of	lives	of	affected	people,	health	resource	use,	health	spending	and	
mortality.		In	Australia,	kidney	disease	accounted	for	2.6%	of	the	total	disability-adjusted	life	years	(DALYs)	faced	by	
the	population	in	2003.		It	is	estimated	that	the	prevalence	of	some	stage	of	chronic	kidney	disease	among	Australians	
aged	25	and	over	is	about	14%.		Renal	replacement	therapy	to	treat	end-stage	kidney	disease	is	expensive.		It	is	
estimated	that	expenditure	on	chronic	kidney	disease	in	2000-01	was	AUD	647	million,	consuming	1.3%	of	the	total	
recurrent	health	expenditure.		However,	there	has	been	a	general	lack	of	information	on	chronic	kidney	disease	in	
Australia	due	to	the	limited	national	monitoring	system	and	the	only	recent	development	of	a	clear	definition	of	the	
disease.
3. interventions
Chronic	kidney	disease	is	often	without	symptoms	until	it	has	reached	an	advanced	stage.		Once	a	person	becomes	
aware	of	symptoms,	the	disease	has	often	progressed	close	to	its	end-stage	and	renal	replacement	therapy,	either	renal	
dialysis	or	kidney	transplant,	becomes	inevitable.		In	this	study,	we	compare	the	Incremental	cost-effectiveness	ratio	
(ICER)	for	the	following	treatment	scenarios:
a)	 Current	program	(of	moving	patients	from	dialysis	to	transplantation	when	organs	become	available)	compared	to	
no	treatment;
b)	 Renal	dialysis	only	compared	to	no	treatment;	and
c)	 Current	program	compared	to	renal	dialysis	only.
Alternatively,	preventive	strategies	are	available	to	manage	chronic	kidney	disease	before	symptoms	develop.		There	
are	several	markers	available	for	testing	which	allow	detection	of	renal	damage	at	earlier	stages.		Effective	therapies	to	
slow	progression	of	chronic	kidney	disease	to	end-stage	disease	are	available.		In	this	study,	we	investigated	the	cost-
effectiveness	of	a	screening	program	for	proteinuria	among	people	aged	25-79	when	they	visit	a	general	practitioner	
for	another	reason.		We	separately	consider	people	with	and	without	diabetes	mellitus.		The	initial	screening	is	by	
a	urine	dipstick	to	detect	protein	in	the	urine.		Those	testing	positive	are	subsequently	given	a	confirmatory	test	
(protein-creatinine	ratio)	and	an	ultrasound	of	the	kidneys	and	a	full	blood	examination.		Subsequent	life-long	therapy	
with	angiotensin-converting	enzyme	(ACE)	inhibitor	is	then	provided	to	people	identified	with	chronic	kidney	disease	
(Figure	1).		We	also	take	into	account	that	ACE-inhibitors	have	a	protective	effect	on	ischemic	heart	disease	and	stroke.
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Figure	1:		 Event	pathway	of	screening	and	early	treatment
We	compare	the	intervention	with	a	scenario	without	the	intervention,	since	there	is	currently	no	policy	of	screening	for	proteinuria	in	Australia.
4. intervention cost-effectiveness
renal replaceMent tHerapy
All	three	benchmarks	fall	in	the	north-east	(‘health	gain	at	a	cost’)	quadrant	of	the	cost-effectiveness	plane	(Figure	2).		Specifically,	when	
comparing	the	current	program	to	dialysis	only,	the	ICERs	for	both	of	the	populations	fall	under	$50,000	deeming	the	intervention	to	be	a	cost-
effective	one.
Table	1		 Cost-effectiveness	ratios	and	probability	of	being	cost-effective	(renal	replacement	therapy)
Figure	2:	 Cost-effectiveness	of	the	intervention	for	different	benchmark		illustrated	on	a	cost-effectiveness	plane	with	AU$	50,000	per	DALY	
threshold	line	(renal	replacement	therapy)
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Alternatively, preventive strategies are available to manage chronic kidney disease before 
symptoms develop.  There are several markers available for testing which allow detection of 
renal damage at earlier stages.  Effective therapies to slow progression of chronic kidney 
disease to end-stage disease are available.  In this study, we investigated the cost-
effectiveness of a screening program for proteinuria among people aged 25-79 when they visit 
a general practitioner for another reason.  We separately consider people with and without 
diabetes mellitus.  The initial screening is by a urine dipstick to detect protein in the urine.  
Those testing positive are subsequently given a confirmatory test (protein-creatinine ratio) and 
an ultrasound of the kidneys and a full blood examination.  Subsequent life-long therapy with 
angiotensin-converting enzyme (ACE) inhibitor is then provided to people identified with 
chronic kidney disease (Figure 1).  We also take into account that ACE-inhibitors have a 
protective effect on ischemic heart disease and stroke. 
Figure 1:  Event pathway of screening and early treatment 
 
 
 
 
 
We compare the interv ntion with a scenario without the intervention, since there is currently 
no policy of screening for proteinuria in Australia. 
 
4. Intervention cost-effectivenes  
Renal replacement therapy 
All three benchmarks fall in the north-east (‘health gain at a cost’) quadrant of the cost-
effectiveness plane (Figure 2).  Specifically, when comparing the current program to dialysis 
only, the ICERs for both of the populations fall under $50,000 deeming the intervention to be a 
cost-effective one. 
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Table 1  Cost-effectiveness ratios and probability of being cost-effective (renal 
replacement therapy) 
 
Benchmark Cost per DALY (95% uncertainty range) 
Probability of being 
< AUD50,000/DALY 
Current program compared to no treatment 70,000 (65,000 – 76,000) 0% 
Dialysis only compared to no treatment 103,000 (91,000 – 118,000) 0% 
Current program compared to dialysis only 23,000 (20,000 – 26,000) 100% 
 
Figure 2: Cost-effectiveness of the intervention for different benchmark  illustrated on a cost-effectiveness plane 
with AU$ 50,000 per DALY threshold line (renal replacement therapy) 
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Screening and early treatment 
Table 2 provides the ICER and the probabilities of being cost-effective.  The intervention 
targeting different age-groups fall in the north-east (‘health gain at a cost’) or south-east 
(‘health gain and net cost saving’) quadrants of the cost-effectiveness plane (Figure 3).  
Targeting people with diabetes mellitus and those aged 50 years and over have 100% 
probability of being cost-effective.  Net cost-savings would be achieved by focusing on people 
with diabetes mellitus aged 50 and over.  Targeting people without diabetes mellitus over the 
age of 50 is cost-effective, but the probability of a cost-effective resultdecreases to 89% and 
52% for people in the age groups of 40-49 and 25-39, respectively. 
 
Table 1  Cost-effectiveness ratios and probability of being cost-effective (renal 
replacement therapy) 
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screening and early treatMent
Table	2	provides	the	ICER	and	the	probabilities	of	being	cost-effective.		The	intervention	targeting	different	age-groups	fall	in	the	north-east	
(‘health	gain	at	a	cost’)	or	south-east	(‘health	gain	and	net	cost	saving’)	quadrants	of	the	cost-effectiveness	plane	(Figure	3).		Targeting	people	
with	diabetes	mellitus	and	those	aged	50	years	and	over	have	100%	probability	of	being	cost-effective.		Net	cost-savings	would	be	achieved	by	
focusing	on	people	with	diabetes	mellitus	aged	50	and	over.		Targeting	people	without	diabetes	mellitus	over	the	age	of	50	is	cost-effective,	but	
the	probability	of	a	cost-effective	resultdecreases	to	89%	and	52%	for	people	in	the	age	groups	of	40-49	and	25-39,	respectively.
Table	2:	Cost-effectiveness	ratios	and	probability	of	being	cost-effective	(screening	and	early	treatment	of	chronic	kidney	disease)
*	 Dominant	means	the	cost-effectiveness	ratio	falls	in	the	south-east	quadrant,	where	more	benefits	can	be	accrued	at	a	lower	cost	(i.e.	health	gain	with	cost	saving).
Figure	3:	 Cost-effectiveness	of	the	intervention	for	different	target	populations	illustrated	on	a	cost-effectiveness	plane	with	AU$	50,000	per	
DALY	threshold	line	(screening	and	early	treatment	of	chronic	kidney	disease)
5. conclusions
Maintenance	dialysis	is	so	expensive	that	few	individuals	can	afford	treatment	out	of	pocket.	Thus,	the	provision	of	renal	replacement	therapy	
by	the	government	as	a	third-party	funder	has	the	potential	to	reduce	inequalities.	Provision	of	renal	replacement	therapy	on	a	national	scale	
is	already	current	practice.	However,	the	high	cost	associated	with	delivering	dialysis	therapy	may	hinder	such	an	intervention	from	being	
sustainable.
Economists	invoke	the	‘rule	of	rescue’	if	there	is	a	high-cost	but	life-saving	intervention	to	a	small	number	of	individuals	even	if	it	would	not	
otherwise	be	recommended	based	on	cost-effectiveness.	The	rule	of	rescue	may	be	considered	relevant	to	renal	dialysis	for	patients	with	end-
stage	kidney	disease	given	the	low	number	of	donor	organs	facilitating	transplantation,	the	lethal	prognosis,	and	the	demonstrated	effectiveness	
of	dialysis	therapy.	However,	whether	the	numbers	of	patients	are	few	enough	to	evoke	the	rule	of	rescue	may	be	debatable.	The	widespread	
adoption	of	renal	dialysis	in	Australia,	like	in	other	industrialised	countries,	indicates	the	rule	of	rescue	has	been	adopted	implicitly	even	if	this	
may	not	have	been	made	explicit	as	we	do	with	our	analysis. 4 
Table 2: Cost-effectiveness ratio  and probability of being cost-effective (screening and early 
treatment of chronic kidney disease) 
 
Target population 
(age range) 
Cost per DALY 
(95% uncertainty range) 
Probability of being 
< AUD50,000/DALY 
Diabetes mellitus   
50-79 Dominant* (Dominant – 8,000) 100% 
40-49 4,000 (Dominant – 18,000) 100% 
25-39 8,000 (1,000 – 25,000) 100% 
Non-diabetes mellitus   
50-79 12,000 (Dominant – 38,000) 100% 
40-49 33,000 (15,000 – 63,000) 89% 
25-39 49,000 (27,000 – 89,000) 52% 
* Dominant means the cost-effectiveness ratio falls in the south-east quadrant, where more benefits can be accrued at a 
lower cost (i.e. health gain with cost saving). 
 
Figure 3: Cost-effectiveness of the intervention for different target populations illustrated on a 
cost-effectiveness plane with AU$ 50,000 per DALY threshold line (screening and early 
treatment of chronic kidney disease) 
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Maintenance dialysis is so expensive that few individuals can afford treatment out of pocket. 
Thus, the provision of renal replacement therapy by the government as a third-party funder 
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On	the	other	hand,	the	intervention	to	screen	for	proteinuria	and	subsequent	prescription	of	ACE-inhibitor	therapy	is	cost-
effective	for	the	Australian	population.		Targeting	people	with	diabetes	mellitus	would	be	cost-effective	regardless	of	age,	and	
would	yield	more	health	benefits	with	a	net	cost-savings	for	those	aged	50	years	and	over.		Provision	of	the	intervention	to	
people	without	diabetes	mellitus	would	also	be	recommended	if	targeted	at	people	aged	50	and	over.		However,	inclusion	of	
younger	people,	particularly	those	below	the	age	of	40,	has	a	less	favourable	cost-effectiveness.
We	have	modelled	this	as	a	once-off	screening	intervention.	That	is	sufficient	to	establish	the	cost-effectiveness	credentials.	
The	next	step	would	be	to	undertake	more	complicated	modelling	(using	micro-simulation	methods)	to	establish	how	often	
screening	should	be	done.	
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7. aBout ace-prevention
To	aid	priority	setting	in	prevention,	the	Assessing	Cost-Effectiveness	in	Prevention	Project	(ACE-Prevention)	applies	
standardised	evaluation	methods	to	assess	the	cost-effectiveness	of	100	to	150	preventive	interventions,	taking	a	health	sector	
perspective.	This	information	is	intended	to	help	decision	makers	move	resources	from	less	efficient	current	practices	to	more	
efficient	preventive	action	resulting	in	greater	health	gain	for	the	same	outlay.
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